tiprankstipranks
Incyte (CH:ICY)
NASDAQ:ICY
Switzerland Market
ICY
Incyte
RESEARCH TOOLSreports

Incyte (ICY) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

ICY Analyst Ratings

Moderate Buy
20Ratings
Moderate Buy
9 Buy
11 Hold
0 Sell
Based on 20 analysts giving stock ratings to
Incyte
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ICY Stock 12 Month Forecast

Average Price Target

$91.73
Based on 20 Wall Street analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is $91.73 with a high forecast of $113.24 and a low forecast of $76.03. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"75":"$75","114":"$114","84.75":"$84.8","94.5":"$94.5","104.25":"$104.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":113.2361762,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$113.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":91.73081836705882,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$91.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":76.03000401999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$76.03</span>\n  </div></div>","useHTML":true}}],"tickPositions":[75,84.75,94.5,104.25,114],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,92.454,94.05262893846154,95.65125787692307,97.24988681538461,98.84851575384614,100.44714469230769,102.04577363076923,103.64440256923076,105.24303150769231,106.84166044615384,108.44028938461538,110.03891832307693,111.63754726153846,{"y":113.2361762,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,92.454,92.3983706436199,92.34274128723982,92.28711193085972,92.23148257447963,92.17585321809955,92.12022386171945,92.06459450533936,92.00896514895926,91.95333579257918,91.89770643619909,91.84207707981899,91.78644772343891,{"y":91.73081836705882,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,92.454,91.19061569384614,89.9272313876923,88.66384708153845,87.40046277538461,86.13707846923076,84.87369416307692,83.61030985692307,82.34692555076923,81.08354124461538,79.82015693846154,78.55677263230768,77.29338832615385,{"y":76.03000401999999,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":88.302,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.302,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.302,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.302,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.302,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.302,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.302,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.302,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.302,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.302,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.302,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.302,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.454,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$113.24Average Price Target$91.73Lowest Price Target$76.03
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on CH:ICY
Srikripa Devarakonda
Truist Financial
Truist Financial
―
Hold
―
Reiterated
07/02/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY) and Teladoc (NYSE: TDOC)
Barclays Analyst forecast on CH:ICY
Etzer Darout
Barclays
Barclays
CHF94.63
Buy
―
Reiterated
06/29/26
Barclays Keeps Their Buy Rating on Incyte (INCY)
H.C. Wainwright Analyst forecast on CH:ICY
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
CHF113.24
Buy
―
Reiterated
06/29/26
Buy Rating Reaffirmed as Opzelura’s Global Opportunity Expands and DCF-Supported $140 Price Target Is Maintained
UBS Analyst forecast on CH:ICY
Ashwani Verma
UBS
UBS
CHF83.31→CHF91.4
Hold
―
Reiterated
06/25/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY), Guardant Health (NASDAQ: GH) and Biogen (NASDAQ: BIIB)
TD Cowen Analyst forecast on CH:ICY
Marc Frahm
TD Cowen
TD Cowen
CHF100.29
Buy
―
Reiterated
06/22/26
Incyte (INCY) Receives a Buy from TD Cowen
BMO Capital Analyst forecast on CH:ICY
Evan Seigerman
BMO Capital
BMO Capital
CHF60.66→CHF76.03
Hold
―
Upgraded
06/22/26
Evan Seigerman Raises Incyte Price Target to $94 but Maintains Hold on Balanced View of Strategic Progress and Post-2029 LOE Risks
Mizuho Securities Analyst forecast on CH:ICY
Salim Syed
Mizuho Securities
Mizuho Securities
CHF97.87
Buy
―
Reiterated
06/18/26
Analysts Offer Insights on Healthcare Companies: Butterfly Network (NYSE: BFLY) and Incyte (NASDAQ: INCY)
Wells Fargo Analyst forecast on CH:ICY
Derek Archila
Wells Fargo
Wells Fargo
CHF109.19→CHF81.69
Hold
―
Reiterated
06/17/26
Analysts Conflicted on These Healthcare Names: Simulations Plus (NASDAQ: SLP), Incyte (NASDAQ: INCY) and Glaukos (NYSE: GKOS)
Guggenheim Analyst forecast on CH:ICY
Michael Schmidt
Guggenheim
Guggenheim
CHF105.15→CHF110
Buy
―
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY), Rhythm Pharmaceuticals (NASDAQ: RYTM) and Damora Therapeutics (NASDAQ: DMRA)
Bank of America Securities Analyst forecast on CH:ICY
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
CHF100.29
Buy
―
Reiterated
06/15/26
Incyte: Buy Rating Reaffirmed on Promising INCA033989 Data and Risk-Reward, $124 Price Target Unchanged
Goldman Sachs Analyst forecast on CH:ICY
Salveen Richter
Goldman Sachs
Goldman Sachs
CHF80.88
Hold
―
Reiterated
06/15/26
Salveen Richter Reiterates Hold on Incyte as Mid‑Stage INCA033989 Data Align with Expectations Amid Rising Myelofibrosis Competition
Stifel Nicolaus Analyst forecast on CH:ICY
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
CHF99.49
Buy
―
Reiterated
06/15/26
Stifel Nicolaus Sticks to Its Buy Rating for Incyte (INCY)
Morgan Stanley Analyst forecast on CH:ICY
Judah Frommer
Morgan Stanley
Morgan Stanley
CHF83.31
Hold
―
Reiterated
06/15/26
Incyte Rated Hold as Mixed Myelofibrosis Data and Competitive Risks Keep Price Target Unchanged at $103
William Blair Analyst forecast on CH:ICY
Matt Phipps
William Blair
William Blair
―
Hold
―
Reiterated
06/15/26
Matt Phipps Reiterates Hold on Incyte as Encouraging INCA033989 Data Offset by Efficacy Moderation and Phase III Execution Risks
Piper Sandler Analyst forecast on CH:ICY
Allison Bratzel
Piper Sandler
Piper Sandler
CHF88.97
Buy
―
Reiterated
06/09/26
Analysts' Top Healthcare Picks: Incyte (INCY), Zevra Therapeutics (ZVRA)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on CH:ICY
Srikripa Devarakonda
Truist Financial
Truist Financial
―
Hold
―
Reiterated
07/02/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY) and Teladoc (NYSE: TDOC)
Barclays Analyst forecast on CH:ICY
Etzer Darout
Barclays
Barclays
CHF94.63
Buy
―
Reiterated
06/29/26
Barclays Keeps Their Buy Rating on Incyte (INCY)
H.C. Wainwright Analyst forecast on CH:ICY
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
CHF113.24
Buy
―
Reiterated
06/29/26
Buy Rating Reaffirmed as Opzelura’s Global Opportunity Expands and DCF-Supported $140 Price Target Is Maintained
UBS Analyst forecast on CH:ICY
Ashwani Verma
UBS
UBS
CHF83.31→CHF91.4
Hold
―
Reiterated
06/25/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY), Guardant Health (NASDAQ: GH) and Biogen (NASDAQ: BIIB)
TD Cowen Analyst forecast on CH:ICY
Marc Frahm
TD Cowen
TD Cowen
CHF100.29
Buy
―
Reiterated
06/22/26
Incyte (INCY) Receives a Buy from TD Cowen
BMO Capital Analyst forecast on CH:ICY
Evan Seigerman
BMO Capital
BMO Capital
CHF60.66→CHF76.03
Hold
―
Upgraded
06/22/26
Evan Seigerman Raises Incyte Price Target to $94 but Maintains Hold on Balanced View of Strategic Progress and Post-2029 LOE Risks
Mizuho Securities Analyst forecast on CH:ICY
Salim Syed
Mizuho Securities
Mizuho Securities
CHF97.87
Buy
―
Reiterated
06/18/26
Analysts Offer Insights on Healthcare Companies: Butterfly Network (NYSE: BFLY) and Incyte (NASDAQ: INCY)
Wells Fargo Analyst forecast on CH:ICY
Derek Archila
Wells Fargo
Wells Fargo
CHF109.19→CHF81.69
Hold
―
Reiterated
06/17/26
Analysts Conflicted on These Healthcare Names: Simulations Plus (NASDAQ: SLP), Incyte (NASDAQ: INCY) and Glaukos (NYSE: GKOS)
Guggenheim Analyst forecast on CH:ICY
Michael Schmidt
Guggenheim
Guggenheim
CHF105.15→CHF110
Buy
―
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY), Rhythm Pharmaceuticals (NASDAQ: RYTM) and Damora Therapeutics (NASDAQ: DMRA)
Bank of America Securities Analyst forecast on CH:ICY
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
CHF100.29
Buy
―
Reiterated
06/15/26
Incyte: Buy Rating Reaffirmed on Promising INCA033989 Data and Risk-Reward, $124 Price Target Unchanged
Goldman Sachs Analyst forecast on CH:ICY
Salveen Richter
Goldman Sachs
Goldman Sachs
CHF80.88
Hold
―
Reiterated
06/15/26
Salveen Richter Reiterates Hold on Incyte as Mid‑Stage INCA033989 Data Align with Expectations Amid Rising Myelofibrosis Competition
Stifel Nicolaus Analyst forecast on CH:ICY
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
CHF99.49
Buy
―
Reiterated
06/15/26
Stifel Nicolaus Sticks to Its Buy Rating for Incyte (INCY)
Morgan Stanley Analyst forecast on CH:ICY
Judah Frommer
Morgan Stanley
Morgan Stanley
CHF83.31
Hold
―
Reiterated
06/15/26
Incyte Rated Hold as Mixed Myelofibrosis Data and Competitive Risks Keep Price Target Unchanged at $103
William Blair Analyst forecast on CH:ICY
Matt Phipps
William Blair
William Blair
―
Hold
―
Reiterated
06/15/26
Matt Phipps Reiterates Hold on Incyte as Encouraging INCA033989 Data Offset by Efficacy Moderation and Phase III Execution Risks
Piper Sandler Analyst forecast on CH:ICY
Allison Bratzel
Piper Sandler
Piper Sandler
CHF88.97
Buy
―
Reiterated
06/09/26
Analysts' Top Healthcare Picks: Incyte (INCY), Zevra Therapeutics (ZVRA)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Incyte

3 Months
Michael SchmidtGuggenheim
Success Rate
19/25 ratings generated profit
76%
Average Return
+7.83%
Copying Michael Schmidt's trades and holding each position for 3 Months would result in 76.00% of your transactions generating a profit, with an average return of +7.83% per trade.
1 Year
Tazeen AhmadBank of America Securities
Success Rate
17/17 ratings generated profit
100%
Average Return
+32.51%
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +32.51% per trade.
2 Years
David LebowitzCiti
Success Rate
15/15 ratings generated profit
100%
Average Return
+61.34%
Copying David Lebowitz's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +61.34% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ICY Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
26
33
30
41
29
Hold
22
20
19
28
22
Sell
4
3
3
4
3
Strong Sell
0
0
0
0
0
total
52
56
52
73
54
In the current month, ICY has received 29 Buy Ratings, 22 Hold Ratings, and 3 Sell Ratings. ICY average Analyst price target in the past 3 months is 91.73.
Each month's total comprises the sum of three months' worth of ratings.

ICY Financial Forecast

ICY Earnings Forecast

Next quarter’s earnings estimate for ICY is $1.57 with a range of $0.91 to $2.27. The previous quarter’s EPS was $1.46. ICY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ICY has Performed in-line its overall industry.
Next quarter’s earnings estimate for ICY is $1.57 with a range of $0.91 to $2.27. The previous quarter’s EPS was $1.46. ICY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ICY has Performed in-line its overall industry.

ICY Sales Forecast

Next quarter’s sales forecast for ICY is $1.13B with a range of $1.07B to $1.31B. The previous quarter’s sales results were $1.03B. ICY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ICY has Performed in-line its overall industry.
Next quarter’s sales forecast for ICY is $1.13B with a range of $1.07B to $1.31B. The previous quarter’s sales results were $1.03B. ICY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ICY has Performed in-line its overall industry.

ICY Stock Forecast FAQ

What is CH:ICY’s average 12-month price target, according to analysts?
Based on analyst ratings, Incyte’s 12-month average price target is 91.73.
    What is CH:ICY’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:ICY, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Incyte a Buy, Sell or Hold?
        Incyte has a consensus rating of Moderate Buy, which is based on 9 buy ratings, 11 hold ratings and 0 sell ratings.
          What is Incyte’s share price target?
          The average share price target for Incyte is 91.73. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $113.24 ,and the lowest forecast is $76.03. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Incyte?
            Incyte’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.
              How can I buy shares of Incyte?
              To buy shares of CH:ICY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.